Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
Clinical Infectious Diseases · 17.03.2025 · 80 (3) · 566-574
DOI: 10.1093/cid/ciae423 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.08.2024. Verfasst von Onyema Ogbuagu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Multiple, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Background
Lenacapavir is a long-acting human immunodeficiency virus type 1 (HIV-1) capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1.
Methods
This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults with multidrug-resistant HIV-1. Following a 2-week oral lenacapavir loading phase, participants received subcutaneous lenacapavir every 26 weeks with an OBR. HIV-1 RNA, CD4 cell counts, and adverse events were assessed over 104 weeks. One participant did not enter the extension phase.
Results
At Week 104, 44 of 71 participants (62%, 95% confidence interval [CI]: 50; 73) had HIV-1 RNA <50 copies/mL via US Food and Drug Administration (FDA) snapshot algorithm. When missing data (including discontinuations) were excluded, 44 of 54 participants (82%) had HIV-1 RNA <50 copies/mL at Week 104, mean CD4 cell count increased by 122 cells/µL (95% CI: 80; 165), and the proportion of participants with CD4 cell count <200 cells/µL decreased from 64% (46 of 72) at Baseline to 29% (16 of 55). Fourteen participants had treatment-emergent lenacapavir resistance; 7 resuppressed (HIV-1 RNA <50 copies/mL) while maintaining lenacapavir use. There were no Grade 4 or serious treatment-related adverse events. One participant discontinued study drug due to an injection site reaction.
Conclusions
Treatment with subcutaneous lenacapavir in combination with an OBR was well tolerated and resulted in a high rate of virological suppression over 104 weeks. Lenacapavir represents an important treatment option in people with multidrug-resistant HIV-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, Connecticut, USA.
- Université de Paris Cité, Paris, France.
- Département de Maladies Infectieuses, Hôpitaux Saint- Louis, Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.
- INSERM UMR 944, Paris, France.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
- Midway Immunology & Research Center, Fort Pierce, Florida, USA.
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Ogbuagu, O., Molina, J. M., Chetchotisakd, P., Ramgopal, M. N., Sanchez, W., Brunetta, J., Castelli, F., Crofoot, G. E., Hung, C. C., Ronot-Bregigeon, S., Margot, N. A., Wang, H., Dvory-Sobol, H., Rhee, M. S., & Segal-Maurer, S. (2025). Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases, 80(3), 566-574. https://doi.org/10.1093/cid/ciae423
Vancouver
Ogbuagu O, Molina JM, Chetchotisakd P, Ramgopal MN, Sanchez W, Brunetta J, et al. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases. 2025;80(3):566-574. doi:10.1093/cid/ciae423
BibTeX
@article{Ogbuagu2025,
author = {Ogbuagu, Onyema and Molina, Jean-Michel and Chetchotisakd, Ploenchan and Ramgopal, Moti N and Sanchez, William and Brunetta, Jason and Castelli, Francesco and Crofoot, Gordon E and Hung, Chien-Ching and Ronot-Bregigeon, Sylvie and Margot, Nicolas A and Wang, Hui and Dvory-Sobol, Hadas and Rhee, Martin S and Segal-Maurer, Sorana},
title = {Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {3},
pages = {566--574},
doi = {10.1093/cid/ciae423}
}
EUVIMED